Company Filing History:
Years Active: 2011-2015
Title: Gordon D Webster: Innovator in Cancer Treatment
Introduction
Gordon D Webster is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of interleukin-12 variants. With a total of 3 patents to his name, Webster's work is paving the way for advancements in therapeutic methods.
Latest Patents
Webster's latest patents focus on methods of treating cancer using interleukin-12p40 variants that exhibit improved stability. One of his notable inventions involves modified interleukin-12 (IL-12) p40 polypeptides. These modified polypeptides have specific alterations in the IL-12p40 subunit, which eliminate the protease site between positions Lys260 and Arg261. As a result, these modified IL-12p40 polypeptides demonstrate enhanced stability compared to the wild-type mature human IL-12p40 polypeptides. Another patent also addresses nucleic acids encoding interleukin-12P40 variants with improved stability, further emphasizing the importance of his research in this area.
Career Highlights
Gordon D Webster is currently associated with Merck Patent GmbH, where he continues to contribute to the field of biotechnology and pharmaceuticals. His work has garnered attention for its potential impact on cancer therapies, showcasing his dedication to improving patient outcomes.
Collaborations
Webster has collaborated with notable colleagues, including Suzanne P McKenzie and Kin-Ming Lo. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality of his research.
Conclusion
Gordon D Webster's innovative work in developing interleukin-12 variants represents a significant advancement in cancer treatment. His contributions are vital to the ongoing efforts to improve therapeutic options for patients.